Thai FDA Approves DeepTek's AI-powered Chest X-ray Screening Solution
DeepTek, a provider of AI-powered radiology solutions, announced that its revolutionary chest X-ray screening solution, GenkiTM, has received approval from the Thai Food and Drug Administration (FDA).
GenkiTM will classify scans as normal and abnormal along with further analyzing over 19 different chest pathologies.
By automating the interpretation of chest X-rays, GenkiTM offers immense potential for improving medical diagnosis and treatment efficiency for lung diseases such as tuberculosis, pneumonia, lung cancer, and chronic pulmonary diseases, all of which pose significant health challenges globally.
GenkiTM has already been serving as a lung health screening solution in India and the Philippines and has been instrumental in the ongoing TB Free initiatives in India, where over 300,000 individuals were screened, significantly increasing the detection rate of TB patients, and helping in early identification and timely patient care, the statement from DeepTek added.
The company also claimed that its solution's effectiveness is backed by independent evaluations conducted by esteemed organizations like StopTB Partnership, Friends for International TB, and several others across the globe, which shows that the performance of AI is at par with human experts.
DeepTek is actively collaborating with hospitals and medical institutions across Thailand to integrate its AI solutions into their existing radiology workflows.
Commenting on the Thai FDA approval, Ajit Patil, Co-Founder of DeepTek, said "Thailand has gained a reputation for offering excellent medical resources and healthcare services by thinking ahead of time. The recent approval from the Thai regulatory body testifies to the readiness of the country to adopt AI into their healthcare services. We are happy to have partnered with leading healthcare providers in Thailand and be backed by Shimadzu Asia Pacific. We look forward to tapping vast opportunities in Thailand and beyond.”
